Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04470726 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

A Phase 1 study, sponsored by AiViva BioPharma.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT04470726 is a Phase 1 study that has completed, run by AiViva BioPharma. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04470726, a Phase 1 study, has completed, sponsored by AiViva BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

Interventions

  • DRUG AIV001
  • DRUG AIV001 suspension

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2020-08-18
Est. Completion 2023-07-28
Phase Phase 1

Sponsor

AiViva BioPharma

5 total trials

What the Registry Record Tells You About NCT04470726

The ClinicalTrials.gov registry entry for NCT04470726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiViva BioPharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which AIV001 is the first listed.

NCT04470726 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04470726 about?

NCT04470726 is a clinical study titled "Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype". To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

What is the current status of trial NCT04470726?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-08-18. Estimated completion is 2023-07-28.

What interventions are being tested in trial NCT04470726?

The interventions under investigation include: AIV001 (DRUG), AIV001 suspension (DRUG).

Who is sponsoring clinical trial NCT04470726?

This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.